Bungie's latest title, Marathon, an extraction shooter, has underperformed, leading to a significant $765 million impairment loss for Sony in the last fiscal year. Despite Marathon's struggles and a slowly falling player base since its release in Q4 2025, Bungie developers remain committed, stating they're "in it for the long haul". The setback contrasts with Sony's overall 12% operating income gain, attributed to network services and favorable exchange rates.
Bungie has reduced the Biotoxic Disinjector's damage by 35%, aiming to balance gameplay in Marathon. Community reactions are mixed on the effectiveness.
